Physicians

Departments / Divisions

• Medicine / Medicine - Oncology
• Radiation Oncology

Address
DUMC 3893
Durham, NC 27710

Appointment Telephone
919-668-6688

Office Telephone
919-668-1748

Fax Telephone
919-681-0874

Training

• MD, Mayo Medical School (Minnesota), 1994

Residency

• Internal Medicine, Duke University Medical Center, 1997

Fellowship

• Hematology/Oncology, Duke University Medical Center, 2000

Clinical Interests
Breast cancer angiogenesis, breast cancer in younger women, hormonal therapy, neoadjuvant therapy for breast cancer

Research Interests
Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Adelphi Research by Design LLC
• Curry Rockefeller Group LLC
• E-Squared Cummunications LLC
• Educational Concepts
• Emory University
• Genentech, Inc (Roche Holding)
• GlaxoSmithKline
• Imedex,LLC
• Institute for Medical Education
• Mayo Clinic
• MedLearning
• Medcases,LLC
• Novartis
• Per Group LP
• Philips Gilmore Oncology Communications
• Research To Practice
• Sanofi-Aventis
• Sarah Cannon Research Institute, LLC
• Statistical Collaborative, Inc
• TRM Oncology Inc
• Xcenda, LLC

Representative Publications
Blackwell KL, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst MW, and Greenberg CS. Plasma D-Dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncology: Vol 18, 600-608, 2000. (2000)

Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Dewhirst MW. Tamoxifen inhibits angiogenesis in estrogen receptor negative animal models. Clin. Cancer Research, November 2000. (2000)

Blackwell KL, Liotcheva V, Haroon ZA, Fung K, Broadwater G, Anderson S, Vredenburgh JJ, Proia A, Greenberg CS, Dewhirst MW, Harris LN. HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis in Primary Breast Tumors. Proceedings of the American Society of Clinical Oncology, 2000. (2000)

Blackwell KL, Nagel SC, McDonnell DP, Dewhirst MW. Estrogen receptor ligands cause variable levels of toxicity in endothelial cells that is partially mediated through the induction of apoptosis. Proceedings of the American Association of Cancer Research. 2000. (2000)

Blackwell KL, Shan S, Nagel SC, McDonnell DP, Broadwater G, Harris L, Dewhirst MW. Tamoxifen Inhibits Angiogenesis through possible Estrogen Receptor Independent Effects on Endothelial Cells. Breast Cancer Research and Treatment: 57(1), 92, 1999. (1999)